Prot #VX20-121-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Project: Research project

Project Details

StatusActive
Effective start/end date12/13/21 → 12/13/24

Funding

  • Vertex Pharmaceuticals Incorporated (Prot #VX20-121-102)